What the FDA labels say about taking them together
Cyclosporine and golimumab
Golimumab's FDA label of September 9, 2025 names cyclosporine in its drug interactions section; the cyclosporine labels PlainMeds reads (4) do not name golimumab. The golimumab label: “Upon initiation or discontinuation of SIMPONI in patients being treated with CYP450 substrates with a narrow therapeutic index, monitoring of the effect (e.g., warfarin) or drug concentration is recommended and the …”
Check it at the source: the cyclosporine FDA label on DailyMed (effective August 10, 2026, Novartis Pharmaceuticals Corporation); the golimumab FDA label on DailyMed (effective September 9, 2025, Janssen Biotech, Inc.).
What does the cyclosporine label say about golimumab?
Cyclosporine's label (effective August 10, 2026) and its 3 other brand-application labels do not name golimumab in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Neoral), Novartis Pharmaceuticals Corporation, effective August 10, 2026 (SPL set 94461af3-11f1-4670-95d4-2965b9538ae3), via openFDA; the full label on DailyMed
What does the golimumab label say about cyclosporine?
Golimumab label, drug interactionsUpon initiation or discontinuation of SIMPONI ARIA in patients being treated with CYP450 substrates with a narrow therapeutic index, monitoring of the effect (e.g., warfarin) or drug concentration (e.g., cyclosporine or theophylline) is recommended and the individual dose of the drug product may be adjusted as needed.
Source: FDA drug label (Simponi, BLA125289), Janssen Biotech, Inc., effective October 29, 2025 (SPL set f86cb4a7-c358-4136-ae57-b32bda9bba00), via openFDA
Source: FDA drug label (SIMPONI ARIA), Janssen Biotech, Inc., effective September 9, 2025 (SPL set 9e260a47-55af-4c92-8d88-a86ccc767fff), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Cyclosporine | Golimumab | |
|---|---|---|
| Labeled for | Organ transplant rejection, Rheumatoid arthritis | Rheumatoid arthritis, Crohn's disease and ulcerative colitis |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $1.04 per unit 0.05% eye emulsion | $12,890.32 per mL 50 mg/0.5 mL pen injec |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once